Monday, June 13, 2016

BRIEF-Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse

* Catalyst Pharmaceuticals announces agreement with FDA on

confirmatory phase 3 study protocol for Firdapse in

Lambert-Eaton Myasthenic Syndrome

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)